Cue Biopharma announced a private placement expected to close on July 13, 2026, raising approximately $50.0 million to support clinical development and general corporate purposes. Under a Securities Purchase Agreement, investors will acquire 1,418,071 common shares at $33.21 per share and pre-funded warrants for 87,500 shares at $33.209 per warrant, each with a $0.001 exercise price and cashless exercise. Concurrently, a Registration Rights Agreement commits the company to file a resale registration statement within 30 days of closing and maintain effectiveness until all registrable securities are sold. The financing includes investor ownership limits and customary conditions and indemnities.
Agreement 1: Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle
- Agreement type: Securities Purchase Agreement for private placement of equity
- Counterparty: Accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments
- Signed / Effective: Jul 09 2026 / Jul 13 2026
- Reason: Raise capital for clinical development and corporate needs
Agreement 2: Cue Biopharma Grants Investors Resale Registration Rights Following $50 Million Financing
- Agreement type: Registration Rights Agreement covering resale of securities
- Counterparty: Investors from the private placement
- Signed / Effective: Jul 09 2026 / Jul 13 2026
- Duration / Termination: Until all registrable securities are sold
- Reason: Provide resale liquidity to investors
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.